Molecular Formula: C₁₇H₂₃Cl₂NO
Molecular Weight: 328.3 g/mol
Chemical Name: 3α-bis(4-fluorophenyl)methoxy-tropane
Purity: >99%
Capsule Size: 500mcg per capsule
Bottle Size: 30 capsules
Storage: Room temperature, protect from moisture
Product Overview
Tesofensine represents revolutionary triple monoamine reuptake inhibitor technology designed for comprehensive obesity, neuroplasticity, and metabolic research applications. This phenyltropane-derived compound demonstrates exceptional ability to inhibit presynaptic reuptake of norepinephrine, dopamine, and serotonin simultaneously, creating unique neurochemical conditions for investigating appetite regulation, energy expenditure, and cognitive enhancement. Originally developed for neurodegenerative diseases, tesofensine emerged as the most effective weight-loss agent in clinical trials, producing twice the efficacy of currently approved obesity medications.
Revolutionary Triple Reuptake Mechanism
Tesofensine functions through potent inhibition of all three major monoaminergic transporters with preferential effects on norepinephrine and serotonin systems over dopamine pathways. The compound crosses the blood-brain barrier efficiently, targeting lateral hypothalamic GABAergic neurons to suppress feeding behavior while simultaneously enhancing energy expenditure through sympathetic activation. Unlike traditional stimulants, tesofensine demonstrates no abuse potential while maintaining profound effects on appetite sensations, satiety, and metabolic rate through indirect cholinergic pathway stimulation.
Primary Research Applications
Obesity & Weight Management Research
Clinical validation demonstrates unprecedented 10.6% mean weight loss over 24 weeks, representing twice the efficacy of any approved anti-obesity medication. Phase II trials show 12.8kg average weight reduction with minimal dietary restrictions, positioning tesofensine as breakthrough tool for investigating appetite regulation mechanisms. Research reveals 6-fold increase in weight loss compared to placebo through enhanced satiety sensations and reduced food cravings without taste aversion effects.
Neuroplasticity & BDNF Enhancement Studies
Research demonstrates significant increases in brain-derived neurotrophic factor expression (35% in hippocampal CA3 region) and activity-regulated cytoskeleton protein (65% in CA1 region) following chronic administration. Studies show enhanced adult hippocampal neurogenesis, increased Ki-67 positive cells, and improved synaptic plasticity, making it valuable for investigating cognitive enhancement and antidepressant mechanisms through neurotrophin pathway activation.
Metabolic Regulation Research
Studies reveal improved glucose tolerance with dose-dependent attenuation of insulin responses, reducing fat deposition even under high blood sugar conditions. Research demonstrates 5% increased nighttime energy expenditure and 18g enhanced fat oxidation compared to placebo. Applications include investigating insulin resistance mechanisms, metabolic syndrome pathways, and energy balance regulation through monoaminergic modulation.
Depression & Mood Disorder Studies
Comprehensive research shows antidepressant potential through BDNF upregulation and hippocampal neurogenesis enhancement. Studies demonstrate protection against stress-induced hippocampal atrophy while promoting synaptic transmission improvements. Applications encompass investigating dual obesity-depression treatment approaches, stress resilience mechanisms, and mood regulation through triple monoamine enhancement.
Pain Management Research
Research indicates enhanced anti-nociceptive properties compared to traditional dual reuptake inhibitors through dopaminergic system activation. Studies suggest potential applications in fibromyalgia and chronic pain conditions where monoaminergic dysfunction contributes to pain perception. Applications include investigating pain-mood-weight interconnections and novel analgesic mechanisms.
Mechanism of Action
Triple Reuptake Inhibition: Simultaneous blockade of norepinephrine, serotonin, and dopamine transporters
GABAergic Neuron Suppression: Selective inhibition of lateral hypothalamic feeding-promoting neurons
Cholinergic Enhancement: Indirect stimulation promoting BDNF expression and cognitive function
Appetite Suppression: Centrally-mediated satiety enhancement with prolonged fullness sensations
Energy Expenditure: Increased fat oxidation and nighttime metabolic rate elevation
Weight Rebound Prevention: Unique ability to block post-diet weight regain when combined with other agents
Research Advantages
Superior Efficacy: Twice as effective as approved obesity medications with sustained weight loss
Oral Bioavailability: Convenient once-daily capsule administration eliminating injection requirements
No Abuse Potential: Designed to dissociate stimulant effects from addictive properties
Multi-Target Effects: Simultaneous appetite, mood, cognition, and metabolic applications
Clinical Foundation: Extensive Phase II/III validation with established safety and efficacy profiles
Minimal Side Effects: Well-tolerated with manageable dry mouth, headache, and sleep disturbances
Sustained Action: Long-lasting effects with potential for cycling protocols to maintain efficacy
Quality Specifications
Every Tesofensine capsule batch undergoes comprehensive quality control:
HPLC-MS purity analysis confirming >99% purity
Molecular weight confirmation at 328.3 g/mol
CAS number validation (195875-84-4)
PubChem CID verification (11370864)
Endotoxin testing (<0.1 EU/mg)
Triple reuptake inhibition potency assessment
Certificate of Analysis provided with shipment
Storage & Administration
Store capsules at room temperature in sealed bottle. Protect from moisture and excessive heat. Capsules maintain stability for 24 months when stored properly. Each capsule contains precisely measured 500mcg dose enabling consistent research protocols. For extended studies, cycling protocols may be implemented to maintain efficacy and prevent tolerance development.
Research Use Only: Not for human or veterinary therapeutic applications. Handle according to laboratory safety protocols and institutional research guidelines.